Cost Insights: Breaking Down Gilead Sciences, Inc. and Evotec SE's Expenses

Cost Analysis: Gilead vs. Evotec's Financial Strategies

__timestamp	Evotec SE	Gilead Sciences, Inc.
Wednesday, January 1, 2014	60118000	3788000000
Thursday, January 1, 2015	89690000	4006000000
Friday, January 1, 2016	105953000	4261000000
Sunday, January 1, 2017	175062000	4371000000
Monday, January 1, 2018	263389000	4853000000
Tuesday, January 1, 2019	313546000	4675000000
Wednesday, January 1, 2020	375181000	4572000000
Friday, January 1, 2021	466491000	6601000000
Saturday, January 1, 2022	577383000	5657000000
Sunday, January 1, 2023	606375000	6498000000
Monday, January 1, 2024		28675800000

Unveiling the hidden dimensions of data

Unveiling Cost Dynamics: Gilead Sciences, Inc. vs. Evotec SE

In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Gilead Sciences, Inc. and Evotec SE from 2014 to 2023. Over this period, Gilead Sciences consistently outpaced Evotec SE, with costs peaking at approximately $6.6 billion in 2021, a 74% increase from 2014. Meanwhile, Evotec SE's costs grew by nearly 910%, reaching around $606 million in 2023. This stark contrast highlights Gilead's expansive operations compared to Evotec's more modest scale. Notably, both companies experienced significant cost increases in 2021, reflecting broader industry trends. As the pharmaceutical sector continues to innovate, these insights offer a glimpse into the financial strategies shaping two key players.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025